News | October 27, 2022
Dabur India posts consolidated Q2 FY2023 PAT at Rs. 490.06 Cr
The company has reported total income of Rs. 3109.77 crores during the period ended September 30, 2022
The company has reported total income of Rs. 3109.77 crores during the period ended September 30, 2022
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Ketorolac Tromethamine Tablets are indicated to relieve moderately severe pain, usually after surgery.
The CRL did not identify any outstanding scientific issues with the product.
Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
The company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.
Subscribe To Our Newsletter & Stay Updated
